The Medidata partnership is an interesting one. Medidata are a significant global player in clinical research and a subsidiary of Dassault Systèmes (market cap $42b euro). They see the CNS space as an important growth driver and, judging by this morning's webinar, CGS is crucial to that.
Medidata can unlock huge channels for CGS through their existing business, but I'm also starting to think that, given the importance of CNS to Medidata and the obvious synergies, CGS could be a strategic acquisition for them.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.81 |
Change
-0.030(1.63%) |
Mkt cap ! $307.2M | |||
| Open | High | Low | Value | Volume |
| $1.85 | $1.86 | $1.81 | $297.4K | 161.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 349 | $1.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 10000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |